Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)
ObjectiveRett syndrome (RTT) is a severe, rare and chronic disease that necessitates long-term treatment. In March 2023, trofinetide was approved by the US Food and Drug Administration as the first treatment for RTT. Because of the constraints of clinical trials, certain delayed and infrequent adver...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2026-01-01
|
| סדרה: | Frontiers in Pharmacology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1643906/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|